Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of the SEPAR-ALAT Asthma Exacerbation Severity Classification.

Archivos de bronconeumologia·2026

Same author

Clinical, Behavioral and Neuroradiological Phenotype in an Italian Cohort of Patients With Xia Gibbs Syndrome: A Multicenter Cross-Sectional Study and Systematic Literature Review.

American journal of medical genetics. Part A·2026

Same author

Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study.

Open forum infectious diseases·2026

Same author

[Potentially toxic phthalates in clothing and toys: definition, sources, and strategies for the protection of public health.]

Recenti progressi in medicina·2026

Same author

ALAT-SEPAR Consensus on the Definition and Classification of Asthma Exacerbations by Severity: A Move Toward International Standardization.

Open respiratory archives·2025

Same author

The burden of extra uterine growth restriction on postnatal growth in very low birth weight preterm newborns.

BMC pediatrics·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Endpoints in paediatric oncology.

Paolo Paolucci¹, Vera Cioni, Elena Bigi

¹Department of Mother and Child, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, Italy. paolo.paolucci@unimore.it

European Journal of Clinical Pharmacology

|November 19, 2010

Summary

This summary is machine-generated.

This review examines clinical trial endpoints in pediatric oncology, highlighting differences from adult trials. Pediatric cancer research prioritizes cure rates and quality of life, with unique trial designs due to rarity.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jun 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

Pediatric Oncology
Clinical Trial Design
Biostatistics

Background:

Clinical trial endpoints are crucial outcome measures in oncology research.
Paediatric oncology trials face unique challenges due to the rarity of childhood cancers.
Differences in endpoint selection and interpretation exist between paediatric and adult oncology.

Purpose of the Study:

To critically analyze endpoints used in paediatric oncology clinical trials.
To compare paediatric oncology endpoints with those used in adult oncology.
To discuss the implications of endpoint selection for therapeutic assessment and drug development in children.

Main Methods:

Literature review and analysis of clinical trial data.
Critical evaluation of primary, secondary, and surrogate endpoints.
Comparison of endpoint strategies in paediatric versus adult oncology settings.

Main Results:

Childhood cancer rarity necessitates large-scale, multinational clinical trials.
Multiplicity interference is less common in paediatric oncology trials compared to adult trials.
Cure rate is a highly consistent and relevant endpoint in paediatric oncology, differing from adult trials.

Conclusions:

Improving survival and quality of life are primary goals in paediatric cancer treatment.
Clinical trial endpoints are vital for answering research questions and guiding treatment.
New regulations aim to enhance paediatric oncology research and drug availability.